Sacituzumab tirumotecan improves survival in treated endometrial cancer trial

A phase 3 trial (TroFuse-005) compared the antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) with treatment of physician's choice in 776 patients with advanced or recurrent endometrial cancer who had progressed after platinum-based chemotherapy and immunotherapy. The trial reported median progression-free survival of 7.2 months with sac-TMT versus 3.9 months with TPC, and median overall survival of 19.0 months versus 12.1 months, though grade 3 or higher adverse events were more frequent with sac-TMT (69% vs 57%). The authors state these findings support sac-TMT as a new standard of care option for this patient population.

Most relevant for: Patients with advanced or recurrent endometrial cancer who have progressed after platinum-based chemotherapy and immunotherapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.